1. Home
  2. XFOR vs MGNX Comparison

XFOR vs MGNX Comparison

Compare XFOR & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XFOR
  • MGNX
  • Stock Information
  • Founded
  • XFOR 2014
  • MGNX 2000
  • Country
  • XFOR United States
  • MGNX United States
  • Employees
  • XFOR N/A
  • MGNX N/A
  • Industry
  • XFOR Biotechnology: Biological Products (No Diagnostic Substances)
  • MGNX Biotechnology: Pharmaceutical Preparations
  • Sector
  • XFOR Health Care
  • MGNX Health Care
  • Exchange
  • XFOR Nasdaq
  • MGNX Nasdaq
  • Market Cap
  • XFOR 118.4M
  • MGNX 99.7M
  • IPO Year
  • XFOR N/A
  • MGNX 2013
  • Fundamental
  • Price
  • XFOR $1.61
  • MGNX $1.69
  • Analyst Decision
  • XFOR Strong Buy
  • MGNX Hold
  • Analyst Count
  • XFOR 3
  • MGNX 9
  • Target Price
  • XFOR $72.33
  • MGNX $5.33
  • AVG Volume (30 Days)
  • XFOR 1.8M
  • MGNX 737.5K
  • Earning Date
  • XFOR 08-11-2025
  • MGNX 08-12-2025
  • Dividend Yield
  • XFOR N/A
  • MGNX N/A
  • EPS Growth
  • XFOR N/A
  • MGNX N/A
  • EPS
  • XFOR 2.16
  • MGNX N/A
  • Revenue
  • XFOR $31,364,000.00
  • MGNX $154,050,000.00
  • Revenue This Year
  • XFOR $1,300.08
  • MGNX N/A
  • Revenue Next Year
  • XFOR N/A
  • MGNX N/A
  • P/E Ratio
  • XFOR $0.74
  • MGNX N/A
  • Revenue Growth
  • XFOR N/A
  • MGNX 255.31
  • 52 Week Low
  • XFOR $1.38
  • MGNX $0.99
  • 52 Week High
  • XFOR $26.83
  • MGNX $5.10
  • Technical
  • Relative Strength Index (RSI)
  • XFOR 40.77
  • MGNX 57.96
  • Support Level
  • XFOR $1.55
  • MGNX $1.49
  • Resistance Level
  • XFOR $2.22
  • MGNX $1.64
  • Average True Range (ATR)
  • XFOR 0.20
  • MGNX 0.13
  • MACD
  • XFOR 0.06
  • MGNX 0.00
  • Stochastic Oscillator
  • XFOR 26.44
  • MGNX 53.66

About XFOR X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: